IMA001 / Nuvamid, LGD SARL - LARVOL DELTA

Characterization of sickle cell disease-associated organ dysfunction in aged Townes HbSS mice and effect of IMA001 (ASH 2025) - "This study characterizes organ damage in 7-9-month-old HbSS mice and documents its furtherprogression over an 8-week experimental period. HbSS mice displayed progressive cardiac remodelingand dysfunction and modest renal and hepatic impairments. Administration of IMA001 for 8 weeks waswell tolerated and demonstrated potential cardioprotective effects through improving diastolic function,as well as a reduction in liver lesion incidence."

Preclinical • Anemia • Cardiovascular • Genetic Disorders • Hematological Disorders • Hepatology • Liver Failure • Sickle Cell Disease • KIM1

IMA001 Is a Novel Therapeutic Molecule That Improves Hematological Parameters during Vaso-Occlusion in Sickle Cell Disease In Vivo (ASH 2024) - "Conclusion : Administration for 36 days of IMA001 to sickle Townes HbSS mice showed a potent protective effect during an acute episode of vaso-occlusion by reducing intravascular hemolysis and by inhibiting microvascular stasis and was well tolerated. Our study demonstrates the potential of IMA001 as a safe and effective molecule to improve hematological and vascular parameters during VOCs."

Preclinical • Anemia • Genetic Disorders • Hematological Disorders • Inflammation • Sickle Cell Disease

IMA001 Is a Novel Therapeutic Molecule That Reduces Sickling and Hemolytic Anemia Markers in a Sickle Cell Disease Mouse Model (ASH 2024) - "This feature on anemia alleviation has a direct physiological effect in the Townes mice, as highlighted by the mitigation in spleen size indicating a positive impact on stress erythropoiesis. Overall, these data demonstrate the potential of IMA001 as a promising new, safe and effective treatment for SCD."

Preclinical • Anemia • Genetic Disorders • Hematological Disorders • Inflammation • Sickle Cell Disease